Use of convalescent plasma therapy in eight individuals with mild COVID-19. (January 2021)

• Record Type: Journal Article
• Authors: Ji, F.; Liu, W.; Hao, D.-A.; Cheng, J.; Tong, X.-C.; Hao, J.-G.; Wang, L.-P.; Li, C.-Y.; Dai, M.-J.; Yan, X.-B.
• Is Part Of: New microbes and new infections. Volume 39(2021)
• Publication Date: 2021-01
• Subjects: Convalescent plasma -- coronavirus disease 2019 -- immunity -- severe acute respiratory syndrome coronavirus 2 -- treatment; Medical microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; Microbiology -- Periodicals; Communicable Diseases -- Periodicals; Infection -- Periodicals; 616.9041
• DOI: 10.1016/j.nmni.2020.100814
• Languages: English
• ISSNs: 2052-2975

Abstract

Abstract: Coronavirus disease 2019 (COVID-19) is still a global epidemic. Several studies of individuals with severe COVID-19 regard convalescent plasma (CP) transfusion as an effective therapy. However, no significant improvements are found in randomized clinical trials of CP treatment. Until now, data for individuals with mild COVID-19 transfused CP were lacking. This study recruited eight individuals with mild COVID-19 who received at least one dose of CP transfusion. After CP therapy, the clinical symptoms of all individuals improved. Lymphocyte counts tended to increase, and lactate dehydrogenase, creatine kinase and aspartate aminotransferase tended to decrease. However, C-reactive protein increased transiently in three individuals. The median time for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid test to become negative was 2.5 days after CP transfusion. The study shows the potential benefits of CP. Meanwhile, CP probably enhances the inflammatory response to SARS-CoV-2 temporarily in people with insufficient antiviral immunity. However, the effects of CP are not permanent.